Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Larimar Therapeutics ( (LRMR) ) has provided an announcement.
On February 25, 2026, Larimar Therapeutics, Inc. entered into an underwriting agreement with a syndicate led by J.P. Morgan Securities LLC and Guggenheim Securities, LLC for a public offering of 20,000,000 shares of its common stock at $5.00 per share. The underwriters exercised in full a 30-day option on February 26, 2026 to purchase an additional 3,000,000 shares, bringing expected net proceeds to approximately $107.6 million, with all shares sold by the company.
The transaction, conducted under Larimar’s effective shelf registration, is expected to close on February 27, 2026 subject to customary conditions and includes standard representations, warranties, indemnification provisions, and termination rights. The multi-bank syndicate, with J.P. Morgan and Guggenheim as joint bookrunning managers and several additional firms in bookrunner and manager roles, underscores the company’s continued access to capital markets and provides substantial funding for its ongoing operations and strategic initiatives.
The most recent analyst rating on (LRMR) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Larimar Therapeutics stock, see the LRMR Stock Forecast page.
Spark’s Take on LRMR Stock
According to Spark, TipRanks’ AI Analyst, LRMR is a Neutral.
Score is held down primarily by weak financial performance (no revenue, widening losses, and significant cash burn) and bearish technical signals (below key moving averages with negative MACD). Positive clinical/regulatory progress for the lead program provides support, but valuation remains constrained by ongoing losses and no dividend.
To see Spark’s full report on LRMR stock, click here.
More about Larimar Therapeutics
Larimar Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies, with its operations funded in part through public equity offerings of its common stock. The company accesses U.S. capital markets under an effective shelf registration statement to support its business activities and pipeline advancement.
Average Trading Volume: 3,652,483
Technical Sentiment Signal: Buy
Current Market Cap: $315.8M
Find detailed analytics on LRMR stock on TipRanks’ Stock Analysis page.